Ipsen snags an approved cancer drug in $247M M&A deal as another battered biotech sells cheap - Endpoints News

You can add Paris-based Ipsen to the list of discount buyers patrolling the penny stock pack for a cheap M&A deal. The French biotech, which has had plenty of its own problems to grapple with, has swooped in to buy Epizyme $EPZM for $247 million in cash and a…

Astellas Pharma, which has been at the forefront of uncovering the risks associated with gene therapies delivered by adeno-associated viruses, must take another safety alarm head-on. The FDA has sla… [+765 chars]

full article...